Stock Ratings / Health Care / BRVE / earnings

TRVI (30) XERS (64) SLS (38) SRPT (27) ⌘ Pro Terminal →

Braveheart Bio Inc. (BRVE) Next Earnings Date & Expected ±12.5% Move

$21.51 +1.51% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $21.53

Braveheart Bio Inc. (BRVE) carries a Roarable Rating of D (Sell) with 46/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (46/100 · D) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D • SELL / AVOID Cap $1.94B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on BRVE Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is BRVE stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Braveheart Bio Inc. (NASDAQ: BRVE) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 46/100 at a spot price of $21.51 (+1.51% 1D, market cap $1.94B). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, BRVE ranks #326 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does BRVE compare to TRVI and XERS in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), BRVE carries a Roarable D (46/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, TRVI (Trevi Therapeutics Inc.) holds a E grade (30/100 RQD, P/E N/A, ROIC -23.7%, cap $1.93B) and XERS (Xeris Biopharma Holdings Inc.) posts a C grade (64/100 RQD, P/E N/A, ROIC 16.0%, cap $1.95B). Among the 5-stock peer group, BRVE leads on earnings multiple (N/A) while XERS leads on capital efficiency (16.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for BRVE?

▼

Per BRVE's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002131524), Braveheart Bio Inc. generated $0 in revenue, $0 in net income, and $0 in free cash flow against $89.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $21.53 (+0.08%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 10/20 (D) • 1.4% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (46/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-6.1% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-5.4% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for BRVE)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (46/100 Composite)

🔍 WHY BRVE SCORES 46/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (28% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Cash Engine Quality+10/20 pts (22% of score)

SEC XBRL FY 2025 (10-K): 1.4% FCF Margin ($54.2M FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning5/20 pts (-15 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-15 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$19.33+4.9% Next Q

Q2 (-2Q)

Grade D$20.27+7.6% Next Q

Q3 (-1Q)

Grade D$21.82-1.4% Next Q

Current

Grade D$21.51-6.1% Hist 90D α

Trajectory: E (38) → D (46)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a BRVE Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While BRVE currently carries a cautious 46/100 (D) rating due to Whale & Options Positioning (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($23.27) and Max Pain ($22.59) forces dealer call-delta covering toward $33.60.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $BRVE• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “BRVE Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 46%NO 54%Trade / Inspect Odds →

NEXT EST. WINDOW: Dec 30, 2026 (~57 DAYS)

Historical OHLCV Volatility ±12.5% Swing Band

±$2.69 Expected Swing

MODEL EARNINGS SETUP GAUGE

BRVE Quantitative Pre-Earnings Setup: 46/100

Trailing EPS: $4.25 • YoY Revenue Growth: 12.4%

Model Bullish Setup (46/100)Model Risk Weight (54/100)

Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).

LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

Period	Filed	Revenue	Net Profit	Free Cash Flow	Gross Margin
FY 2025	2025-12-31	$0	$0	$0	52%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring BRVE)

✓Walkthrough of BRVE's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

BRVE // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -27.82%▼ DESCENDING CHANNEL

2026-11-03O $21.19H $21.51L $21.19C $21.51VOL 533.7K

RES: $26.64SUP: $13.56SMA50: $23.27SMA200: $24.14

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

BRVE Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 BRVE Butterfly Map → + Track BRVE →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on BRVE today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for BRVE. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for BRVE today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (BRVE)

Health Care Rank #326 of 1016 ⚔️ TRVI vs BRVE Full Matrix →

1. Head-to-Head Health Care Peer Comparison (BRVE vs. TRVI, XERS, SLS, SRPT)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Braveheart Bio Inc. (BRVE) ranks #326 by composite RQD confidence (46/100, grade D) and #261 by equity capitalization ($1.94B). Within this direct 5-issuer industry benchmark cohort, BRVE leads on earnings valuation at N/A trailing P/E, while XERS leads on capital efficiency and profitability with 16.0% ROIC and — gross margin. XERS currently holds the highest overall quantitative score in the immediate peer group at 64/100 (C) compared with BRVE at 46/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
BRVE ACTIVE Braveheart Bio Inc.	D	46/100	—	—	—	+1.51%	$1.94B	Benchmark Subject
TRVI Trevi Therapeutics Inc.	E	30/100	—	—	-23.7%	-1.81%	$1.93B	/trvi-vs-brve →
XERS Xeris Biopharma Holdings Inc.	C	64/100	—	—	16.0%	-0.37%	$1.95B	/xers-vs-brve →
SLS SELLAS Life Sciences Group Inc.	D-	38/100	—	—	-21.8%	-4.68%	$1.95B	/sls-vs-brve →
SRPT Sarepta Therapeutics Inc.	E	27/100	—	96.0%	-35.0%	-3.17%	$1.97B	/srpt-vs-brve →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2025–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0002131524

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Braveheart Bio Inc. (BRVE) reported GAAP revenue of $0 , GAAP net income of $0, operating cash flow of $0, and free cash flow of $0 . On the balance sheet, BRVE closed FY2025 with $89.3M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: N/A).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	$0	—	—	$89.3M	—

3. BRVE Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is BRVE stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does BRVE compare to TRVI and XERS in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for BRVE?

Where is BRVE trading relative to its 50-day, 200-day, and 52-week technical levels?

BRVE last traded at $21.51 (+1.51% on volume of 533,674 shares), positioning the stock -7.56% below its 50-day simple moving average ($23.27) and -10.89% below its 200-day simple moving average ($24.14). Across its 52-week range of $17.86 to $32.00, BRVE sits at the 25.8% percentile with a 14-day RSI of 49.4 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($18.82 to $24.20).

BRVE Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

When is BRVE's next earnings date?

Based on SEC filing cadence, Braveheart Bio Inc. (BRVE)'s next quarterly reporting window is estimated around Dec 30, 2026.

How much is BRVE stock expected to move on earnings?

Volatility modeling currently projects a ±12.5% event move for BRVE, spanning a range between $18.82 and $24.2.

Direct Sub-Reports: BRVE RQD Cockpit BRVE 12M Forecast BRVE Earnings & Move BRVE Dividends & DRIP BRVE Insiders & 13F BRVE Whale Options BRVE Profit Sankey BRVE News & Why

ROARABLE RATING BRIEF • RQD 46/100 (D) ✓ STAGE-C NUMBER FIREWALL VERIFIED

BRVE — Braveheart Bio Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T14:12:52Z

Roarable Rating Brief: What This Means to a Prospective Investor

The Roarable RQD rating is 46 out of 100, graded D, with the verdict "Roarable Sell — Underperform / Distribution Warning" (per the Roarable RQD rating). The five pillars are:

Fundamental Cash Engine: 10 / 20. Per the Roarable RQD rating, this reflects ROIC of 0% and FCF yield of 0%. For a prospective investor, the rating indicates no measurable return on invested capital and no free-cash-flow yield in the source data.
Whale / 13F Flow: 5 / 20. Per the Roarable RQD rating, this pillar covers institutional accumulation and options positioning. Its low score points to weak institutional support in the source data, though no holder-level detail is provided in <holders>.
Insider Conviction: 9 / 20. Per the Roarable RQD rating, this covers SEC Form 4 and Congressional PTR cluster flow. The source data does not include the underlying transactions, so the score cannot be traced to specific trades.
Macro Regime Fit: 9 / 20. Per the Roarable RQD rating, beta is 1.0 with a sector-sensitivity component. A beta of 1.0 means the stock is rated as moving in line with the market, and the score indicates limited regime-fit advantage.
Forensic Balance Sheet: 13 / 20. Per the Roarable RQD rating, Altman Z is 2.5, Piotroski F is 6/9, and Debt/Equity is 0.5. This is the strongest pillar, indicating a comparatively sounder balance sheet than the other four pillars.

Taken together, the rating points to a weak cash-generation profile and weak institutional and insider signals, partly offset by balance-sheet resilience. A prospective investor would weigh the upside drivers (balance-sheet strength, the 52-week high of $32 as a reference point) against valuation tradeoffs, since no earnings-based valuation multiples are available in the source data.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025 (filed 2025-12-31)	$0.0M	$0.0M	$0.0M	N/A	N/A	$89.2M	N/A

Per the SEC financials, reported revenue, operating income, and net income are all $0.0M for FY 2025, and gross, operating, and net margins are 0% (per the market data). ROIC is 0% and FCF yield is 0% (per the market data). Per the Roarable RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 6/9, with Debt/Equity of 0.5. Reported cash is $89.2M, while the debt figure is listed as N/A in the SEC financials.

Recent Catalysts & News Wire Analysis

Per the recent news feed, the catalysts are headline-level items, all flagged YELLOW under the MARKET WIRE impact label:

Seeking Alpha coverage of the stock's non-obstructive HCM therapeutic window (published roughly 1 hour before the data timestamp).
Simply Wall St coverage with a forecast and analyst-predictions framing.
Stock Titan coverage of 52-week results for a heart drug being slated for a late-breaking presentation.
MarketBeat coverage reporting shares down 7.6%.
Quiver Quantitative coverage of an investor and analyst webinar on BHB-1893 and the hypertrophic cardiomyopathy program.
Stock Titan coverage of two cardiologists discussing the developing treatment for a heart-muscle-thickening condition.

Risk watch items in this feed include the reported 7.6% share decline and the price action captured in the market data (change of -2.62% on the day). The Butterfly graph reports no proprietary signals.

Open Questions

What products or clinical programs generate BRVE's economics, and what is the revenue path given $0.0M reported revenue for FY 2025?
What is the debt figure, given the financials list debt as N/A while Debt/Equity is cited as 0.5?
What specific institutional and insider transactions underlie the 5/20 whale-flow and 9/20 insider-conviction pillars?
What drove the 7.6% share decline referenced in the MarketBeat coverage, and how does it relate to the 52-week range of $17.86 to $32?
What are the reported EPS, free cash flow, and earnings-based valuation multiples, which the source data marks as unavailable?

BRVE Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Braveheart Bio Inc. (BRVE) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to BRVE Debate Forum (3) ↓

🟡 MARKET WIRE Seeking Alpha • 17h ago

Braveheart Bio: In Non-Obstructive HCM, The Therapeutic Window Is The Product (BRVE)

Seeking Alpha report covering Braveheart Bio Inc. (BRVE) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Simply Wall St • 20h ago

Braveheart Bio (NasdaqGM:BRVE) Stock Forecast & Analyst Predictions

Simply Wall St report covering Braveheart Bio Inc. (BRVE) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 23h ago

A heart drug’s 52-week results are headed for a late-breaking presentation

Stock Titan report covering Braveheart Bio Inc. (BRVE) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE MarketBeat • 1d ago

Braveheart Bio (NASDAQ:BRVE) Shares Down 7.6% - Time to Sell?

MarketBeat report covering Braveheart Bio Inc. (BRVE) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Quiver Quantitative • 1d ago

Braveheart Bio to Host Investor and Analyst Webinar on BHB-1893 and Hypertrophic Cardiomyopathy Program

Quiver Quantitative report covering Braveheart Bio Inc. (BRVE) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

Two heart doctors will discuss Braveheart Bio's developing treatment for a condition that thickens heart muscle.

Stock Titan report covering Braveheart Bio Inc. (BRVE) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE MarketBeat • 1d ago

Braveheart Bio (NASDAQ:BRVE) Stock Price Up 7.9% - Should You Buy?

MarketBeat report covering Braveheart Bio Inc. (BRVE) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Quiver Quantitative • 1d ago

Braveheart Bio Announces Upcoming AHA 2026 Presentations, Including 52-Week Extension Data for BHB-1893 in Obstructive HCM

Quiver Quantitative report covering Braveheart Bio Inc. (BRVE) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

BRVE Bull vs. Bear Conversation Board — What's Your Call at $21.51?

🐂 50% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON BRVE 🐻 50% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk ⚖️ DEBATE HOST 🎯 Target: $22.89 (+8.0%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is BRVE (D • RQD 46/100) a Buy at $21.19?

Welcome to the BRVE (Braveheart Bio Inc.) Roar Pit. Current RQD Composite is 46/100 (Roarable Sell — Underperform / Distribution Warning) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

SH ShortSeller_Dan Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $17.38 (-18.0%)

Spot @ $21.19

Pump the brakes on BRVE — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on BRVE, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Braveheart Bio Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

QU QuantViper Verified K Arena Trader 🐂 BULLISH 🎯 Target: $25.64 (+21.0%)

Spot @ $21.19

BRVE cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on BRVE, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $21.19 (52-wk range $17.86 - $32.00), any beat on forward guidance forces shorts and underweight funds to chase.